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Abstract
After prosperous domino reactions towards benzopyrans, the products were used as the starting material in Lewis acid catalyzed
and organocatalytic Diels–Alder reactions to build up a tricyclic system. Herein, an asymmetric induction up to 96% enantiomeric
excess was obtained by the use of imidazolidinone catalysts. This approach can be utilized to construct the tricyclic system in
numerous natural products, in particular the scaffold of tetrahydrocannabinol (THC) being the most representative one. Compared
with other published methods, condensation with a preexisting cyclohexane moiety in the precursor is needed to gain the hetero-
genic tricycle systems, whereas we present a novel strategy towards cannabinoid derivatives based on a flexible modular synthesis.
Introduction
The Diels–Alder reaction is one of the most important processes
for carbon–carbon-bond formation in organic chemistry [1,2].
Especially in the synthesis of natural products it is a widely
used method [3-7]. Some examples are shown in Figure 1. The
first application was the total synthesis of the steroid Cortisone
(1) in 1952 by Woodward et al. [8]. Another example, indi-
cating the importance of the well-known [4 + 2] cycloaddition
in natural-product synthesis, is the first published total syn-
thesis of Taxol (2) by Nicolaou. Two different [4 + 2]-cyclo-
addition reactions were applied to set up each of the two six-
membered rings of the target molecule [9,10]. As a final
example, Dynemicin A (3) should be mentioned, which is an
enediyne consisting of a complex heterocyclic skeleton and a
network of sensitive functional groups, exhibiting antitumor and
antibiotic activity [11]. Three independent research groups
(Schreiber, Myers and Danishefsky) successfully applied
[4 + 2]-cycloaddition reactions in elegant and divergent strate-
gies to reach the target molecule [12-14].
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Figure 2: Intermediates towards the total synthesis of (−)-Δ9-tetrahydrocannabinol (4).
Figure 1: An assortment of natural products synthesized by
Diels–Alder reactions.
Given the importance of the Diels–Alder reaction, considerable
efforts have been directed towards increasing the reaction rate
and enantioselectivity. In the past century, catalysts that were
employed for the enantioselective synthesis of organic com-
pounds, such as pharmaceuticals, agrochemicals, or fine chemi-
cals, were either transition-metal complexes or enzymes. In the
past few years, however, organocatalysis has emerged as an
alternative approach for the catalytic production of enantiomeri-
cally pure organic compounds [15,16]. These organocatalysts
have several important advantages. They are metal-free, usually
nontoxic, stable, moisture-insensitive, and often easy to obtain.
Because of their inertness towards oxygen and moisture, the use
of absolute solvents, inert atmosphere, low temperature, etc., is,
in many instances, not required. Furthermore, due to the
absence of transition metals, organocatalytic methods are
especially attractive for the preparation of compounds that do
not tolerate metal contamination, e.g., active pharmaceutical
ingredients.
MacMillan’s imidazolidinone-based organocatalysts are general
catalysts for a variety of asymmetric transformations. The first
highly enantioselective organocatalytic Diels–Alder reaction
was reported by MacMillan in his pioneering work in 2000
[17]. The activated iminium ion, formed through condensation
of imidazolidinone and an α,β-unsaturated aldehyde, underwent
reactions with various dienes to yield [4 + 2]-cycloadducts in
excellent yields and enantioselectivities.
Results and Discussion
On our way towards a metal-free total synthesis of (−)-Δ9-
tetrahydrocannabinol (4, Figure 2) we developed a convenient
organocatalytic Diels–Alder route to generate the desired
tricycle 5 of a model-system that also represents an alternative
approach to key-intermediate 6 in Danishefsky’s total synthesis
of Dynemicin A (3) [14].
Our strategy, using the [4 + 2]-cycloaddition to obtain the
cannabinoid tricycle system, is able to employ a variety of
dienophiles and, hence, provides a versatile entry to this signifi-
cant group of naturally occurring compounds [18], whereas the
achieved Diels–Alder products can be further modified to gain a
variety of heterocycles. Most published strategies are based on
the use of a preexisting cyclohexane moiety in the starting
material to form the heterogenic tricycle [19-28].
In former experiments of our group [29-31] it became apparent
that without a catalyst no conversion towards the desired prod-
uct occurred. Only the homodimer of the diene 10 could be
isolated. Metal-based Lewis acids (e.g., catechol boronates)
proved to be inefficient or too reactive. Due to the fact that
other groups have used thiourea-derivatives as successful cata-
lysts [32], we decided to test, on a model system, whether these
catalysts could increase the reaction rate based on specific
hydrogen bonds. In our initial screening we used the proven
Schreiner catalyst 1,3-bis(3,5-bis(trifluoromethyl)phenyl)thio-
urea, which gave a satisfying 60% yield. In order to optimize
the yield and to introduce chiral elements, we screened a
number of analogues. These thiourea catalysts 9a–l were easy to
obtain from the corresponding isothiocyanates 7a,b and chiral
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Scheme 1: Synthesis of thiourea catalysts 9a–l.
amines 8a–f in a one-step synthesis (Scheme 1) [33]. The yields
were good to excellent in all procedures (Table 1).
These thioureas were used in an intermolecular Diels–Alder
reaction of diene 10 [36] with acrolein (11) to obtain cannabi-
noid tricycle 5 shown in Scheme 2.
In all cases we only achieved one cis-diastereomer and the car-
bonyl function was always in the 10-position. The reaction was
carried out at low temperature and high dilution to avoid the
dimer formation of diene 10. An increase of the temperature to
40 °C resulted in a higher conversion but unfortunately no
enantioselectivity was observed. We obtained good to excellent
yields from 68% to 99% depending on the substitution of the
thiourea-catalyst 9a–l (Table 2).
When the substitution of the various thioureas 9a–l is further
compared with the obtained yields in the Diels–Alder reaction
(Table 2), the following tendencies are also observed. A notice-
able fact is that, in contrast to the thioureas with a cyclopropyl-
and m-halophenyl-moiety (Table 2, entries 7–9), the corres-
ponding bis(trifluoromethyl)thioureas (Table 2, entries 16–18)
provide a higher conversion.
Next to the previously described thiourea catalysts, we also
analyzed iminium-ion catalysts according to MacMillan on
Beilstein J. Org. Chem. 2012, 8, 1385–1392.
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Table 1: Yields of thiourea syntheses.
Entry R1 R2 Product Yield [%]
1 H Cy (R)-9a [34] 99
2 H Cy (S)-9a [34] 95
3 H Ph (R)-9b 99
4 H Ph (S)-9b [34] 99
5 H p-BrC6H4 (R)-9c 99
6 H p-BrC6H4 (S)-9c 99
7 H cyclopropyl (R)-9d 99
8 H m-ClC6H4 (S)-9e 99
9 H m-BrC6H4 (S)-9f 99
10 CF3 Cy (R)-9g 69
11 CF3 Cy (S)-9g 62
12 CF3 Ph (R)-9h 89
13 CF3 Ph (S)-9h [35] 99
14 CF3 p-BrC6H4 (R)-9i 99
15 CF3 p-BrC6H4 (S)-9i 99
16 CF3 cyclopropyl (R)-9j 91
17 CF3 m-ClC6H4 (S)-9k 99
18 CF3 m-BrC6H4 (S)-9l 76
Scheme 2: Organocatalytic Diels–Alder reaction with thiourea-catal-
ysis.
various model systems (Figure 3) [37]. The effect of these cata-
lysts is based on the formation of iminium ions by conden-
sation of the dienophile bearing a carbonyl group, with the steri-
cally hindered imidazole catalyst. In this way, one side is
shielded and only the other side can be attacked by the diene.
Hence, reaction rate and asymmetric induction are increased.
The synthesis of imidazolidinone catalysts [38] is the premise
for the construction of the demanding amide 13, which was
afforded by the reaction of (S)-phenylalanine methyl ester
hydrochloride (12) with methylamine (Scheme 3). In the second
step of the synthesis, amide 13 was cyclized with different alde-
hydes 14 and addition of catalytic amounts of FeCl3 at high
temperatures into (2S,5S)- or (2R,5S)-imidazolidinone 15
[39,40].
To gain electron-poor catalysts for the degradation of the
dienophilic LUMO in the Diels–Alder reaction and to conse-
quently increase the reaction rate, we used aldehydes with elec-
Table 2: Summarized results of the Diels–Alder reaction.
Entry Catalyst Yield [%]a
1 (R)-9a 97
2 (S)-9a 91
3 (R)-9b 99
4 (S)-9b 85
5 (R)-9c 93
6 (S)-9c 92
7 (R)-9d 74
8 (S)-9e 82
9 (S)-9f 77
10 (R)-9g 68
11 (S)-9g 78
12 (R)-9h 73
13 (S)-9h 88
14 (R)-9i 76
15 (S)-9i 85
16 (R)-9j 87
17 (S)-9k 93
18 (S)-9l 83
aThe conversion is quantitative with respect to 10, the byproduct is the
uncatalyzed dimer of compound 10.
Figure 3: Formation of the iminium-ion.
Scheme 3: Synthesis of electron poor imidazolidinone catalysts.
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Scheme 4: Co-catalyst screening.
tron-withdrawing groups in ortho-, meta- and para-positions
(Scheme 3, Table 3). Reaction with p-nitrobenzaldehyde gave
compound 16 in 66% yield (Figure 4).
Table 3: Results of the conversion of various aldehydes 14 with amide
13.
Entry (Aldehyde 14) R = Catalyst 15 Yield [%]
1
2 t-Bu
(2R,5S)-15a
(2S,5S)-15a
35 [41]
25 [40]
3
4 o-NO2-C6H4
(2R,5S)-15b
(2S,5S)-15b
42
52
5
6 m-F-C6H4
(2R,5S)-15c
(2S,5S)-15c
28
39
7
8 p-F-C6H4
(2R,5S)-15d
(2S,5S)-15d
32
43
9
10 p-Br-C6H4
(2R,5S)-15e
(2S,5S)-15e
39
45
11
12 p-CN-C6H4
(2R,5S)-15f
(2S,5S)-15f
38
46
Figure 4: Crystal structure of the side product from the reaction of 13.
The organocatalytic species 15 were synthesized in moderate
yields. A conspicuous feature is that the yields of the (2S,5S)-
derivatives, with the exception of the tert-butyl substituted cata-
lyst 15a (Table 3, entries 1–2), are always higher than those of
the corresponding (2R,5S)-components (Table 3, entries 3–12).
The configuration of the afforded imidazolidinone catalysts 15
could be confirmed by NOESY experiments and from their
X-ray structures (Figure 5).
Figure 5: Confirmation of the relative configuration with NOESY exper-
iments and X-ray crystal structures of two imidazolidinones 15d and
15f.
Before testing the catalysts in the Diels–Alder reaction, we
analyzed a few co-catalysts with the commercially available
imidazolidinone catalyst 15h. A pentyl-substituted tricycle was
used as a model system (model system II) 19 (Scheme 4,
Table 4).
Hydrochloric acid has been proven to be the best co-catalyst
(Table 4, entry 1), providing cis-19 in good yield and with an
enantiomeric excess of 96%. Even perchloric acid and trifluoro-
acetic acid gave high enantiomeric excesses but in much poorer
yields (Table 4, entries 2 and 3). Using para-toluenesulfonic
acid also afforded cis-19 in good yield, but its enantiomeric
excess could not be determined (Table 4, entry 4). Trifluoro-
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Scheme 5: Screening of imidazolidinone catalysts 15.
Table 4: Summary of the screening of co-catalysts.
Entry Co-catalyst cis-19 trans-19
Yield [%] ee [%] Yield [%] ee [%]
1 HCl (1 M) 51 96 12 91
2 HClO4 (60%) 6 95 10 n.d.
3 TFA 31 96 9 77
4 p-TSA·H2O 50 n.d. 15 90
5 TfOH — — — —
n.d.: not determined.
methanesulfonic acid as co-catalyst only led to decomposition
(Table 4, entry 5).
Under these optimized reaction conditions, we performed a
catalyst screening with the previously synthesized imidazolidi-
none catalysts 15 to study their asymmetric induction
(Scheme 5). As starting material we used compound 17 with the
THC-typical pentyl side chain. The results are summarized in
Table 5.
Table 5: Catalyst screening towards model system II 19.
Entry Catalyst 15 cis-19
R = Yield [%] ee [%]
1 t-Bu (2R,5R)-15h 51 96
2
3 t-Bu
(2R,5S)-15a
(2S,5S)-15a
47
66
−24
−98
4
5 o-NO2-C6H4
(2R,5S)-15b
(2S,5S)-15b
43
50
−89
−29
6
7 m-F-C6H4
(2R,5S)-15c
(2S,5S)-15c
47
55
−78
−38
8
9 p-F-C6H4
(2R,5S)-15d
(2S,5S)-15d
48
54
−79
−37
10
11 p-CN-C6H4
(2R,5S)-15f
(2S,5S)-15f
52
54
−83
−43
The used organocatalysts, having a (S)-configured stereocenter
in the 5-position, should prefer the formation of opposite enan-
tiomers, compared to the commercially available (2R,5R)-15h.
This is indicated by negative enantiomeric excess (Table 5).
Due to low yields of diastereomer trans-19 and the less
successful determination of their enantiomeric excess, Table 5
only contains results for cis-19. Except for in the case of 15a,
we observe tendencies such as the achievement of higher yields
through the use of (2S,5S)-configurated imidazolidinones 15
compared to the yields afforded by (2R,5S)-configurated cata-
lysts 15. There is an opposite trend for the enantiomeric excess,
which is also related to the steric hindrance of the phenyl
substituent, i.e., the smaller the substituent, the lower the enan-
tiomeric excess. Application of the known tert-butylimidazo-
lidinone catalyst 15a provides the highest yield (66%) and
enantiomeric excess (98% ee) with its (2S,5S)-derivate (Table 5,
entry 3).
Conclusion
In conclusion, we have demonstrated that the Diels–Alder reac-
tion of 3-vinyl-2H-chromene with acrolein can be accelerated
with different thioureas, obtained in a one-step synthesis (in
some cases with quantitative conversion). Application of imida-
zolidinone catalysts, inspired by the work of MacMillan,
achieved good yields up to 66% and enantiomeric excesses up
to 98%.
Experimental
Crystal structure determinations
The single-crystal X-ray diffraction study was carried out on a
Nonius Kappa-CCD (9a, 16) or Bruker-Nonius APEXII diffrac-
tometer (9c, 9k, 9l, 15d, 15f) at 123(2) K, by using Mo Kα radi-
ation (λ = 0.71073 Å). Direct methods (SHELXS-97) [42] were
used for structure solution, and refinement was carried out with
SHELXL-97 [42] (full-matrix least-squares on F2). Hydrogen
atoms were localized by difference electron density determin-
ation and refined by using a riding model (H(N) free). The
absolute configurations of 9a, 9c, 9k, 9l were determined by
refinement of Flack’s x-parameter [43] and by using Bayesian
statistics on Bijvoet differences (Hooft’s y-parameter) [44].
The absolute configuration of 15d and 15f could not be deter-
mined reliably by refinement of Flack’s x-parameter [43], nor
by using Bayesian statistics on Bijvoet differences (Hooft’s
y-parameter) [44]. The enantiomer was assigned by reference to
an unchanging chiral center in the synthetic procedure.
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Semi-empirical absorption corrections were applied for 9c and
9l. In 9l one CF3-group is disordered.
9a:  colorless, C15H22N2S, M  = 262.41, crystal size
0.30 × 0.10 × 0.05 mm, monoclinic, space group P21 (no. 4):
a = 8.5864(5) Å, b = 22.2641(17) Å, c = 8.6811(6) Å, β =
117.350(4)°, V  = 1474.04(17) Å3 ,  Z  = 4, ρ(calc) =
1.182 Mg m−3, F(000) = 568, μ = 0.206 mm−1, 8575 reflec-
tions (2θmax = 50°), 4687 unique [Rint = 0.057], 337 parameters,
5 restraints, R1 (I > 2σ(I)) = 0.048, wR2 (all data) = 0.119,
GOOF = 1.09, largest diff. peak and hole 0.235/−0.290 e Å−3,
x = −0.01(8), y = −0.05(5).
9c: colorless, C15H15BrN2S, M = 335.26, crystal size
0.25 × 0.10 × 0.05 mm, monoclinic, space group P21 (no. 4):
a = 16.2276(4) Å, b = 5.5562(2) Å, c = 17.3953(6) Å, β =
108.894(2)°, V = 1483.92(8) Å3, Z = 4, ρ(calc) = 1.501 Mg m−3,
F(000) = 680, μ = 2.899 mm−1, 11045 reflections (2θmax =
50°), 4958 unique [Rint = 0.037], 355 parameters, 5 restraints,
R1 (I > 2σ(I)) = 0.030, wR2 (all data) = 0.072, GOOF = 1.06,
largest diff. peak and hole 0.387/−0.504 e Å−3, x = −0.018(7),
y = −0.012(2).
9k: colorless, C17H13ClF6N2S, M = 426.80, crystal size 0.20 ×
0.10 × 0.05 mm, monoclinic, space group P21 (no. 4): a =
8.1359(6) Å, b =16.2464(13) Å, c = 13.9980(7) Å, β =
92.246(4)°, V = 1848.8(2) Å3, Z = 4, ρ(calc) = 1.533 Mg m−3,
F(000) = 864, μ = 0.381 mm−1, 9231 reflections (2θmax = 50°),
5469 unique [Rint = 0.039], 499 parameters, 5 restraints, R1 (I >
2σ(I)) = 0.055, wR2 (all data) = 0.116, GOOF = 1.16, largest
diff. peak and hole 0.388/−0.252 e Å−3, x = 0.07(9), y = 0.07(4).
9l: colorless, C17H13BrF6N2S, M = 471.26, crystal size 0.35 ×
0.20 × 0.10 mm, monoclinic, space group P21 (no. 4): a =
8.2910(7) Å, b = 16.1565(8) Å, c = 14.0204(10) Å, β =
92.073(3)°, V = 1876.9(2) Å3, Z = 4, ρ(calc) = 1.668 Mg m−3,
F(000) = 936, μ = 2.362 mm−1, 10315 reflections (2θmax =
50°), 5936 unique [Rint = 0.046], 494 parameters, 320 restraints,
R1 (I > 2σ(I)) = 0.056, wR2 (all data) = 0.125, GOOF = 1.09,
largest diff. peak and hole 1.033/−0.634 e Å−3, x = −0.014(11),
y = −0.009(6).
15d: colorless, C17H17FN2O, M = 284.33, crystal size 0.45 ×
0.25 × 0.10 mm, orthorhombic, space group P212121 (no. 19):
a = 8.4559(3) Å, b = 10.5000(4) Å, c = 16.6177(5) Å, V =
1475.43(9) Å3, Z = 4, ρ(calc) = 1.280 Mg m−3, F(000) = 600,
μ = 0.089 mm−1, 11771 reflections (2θmax = 50°), 2602 unique
[Rint = 0.045], 194 parameters, 1 restraint, R1 (I > 2σ(I)) =
0.038, wR2 (all data) = 0.084, GOOF = 1.11, largest diff. peak
and hole 0.135/−0.173 e Å−3, x = −0.8(10), y = 0.3(5).
15f: colorless, C18H17N3O, M = 291.35, crystal size
0.50 × 0.40 × 0.30 mm, monoclinic, space group P21 (no. 4):
a = 6.0140(1) Å, b =15.7002(4) Å, c = 8.5232(2) Å, β =
95.211(2)°, V = 801.44(3) Å3, Z = 2, ρ(calc) = 1.207 Mg m−3,
F(000) = 308, μ = 0.077 mm−1, 13805 reflections (2θmax =
55°), 3628 unique [Rint = 0.027], 203 parameters, 2 restraints,
R1 (I > 2σ(I)) = 0.033, wR2 (all data) = 0.077, GOOF = 1.08,
largest diff. peak and hole 0.181/−0.152 e Å−3, x = −0.2(11),
y = 0.8(5).
16: colorless, C17H17N3O3, M = 311.34, crystal size 0.30 × 0.05
× 0.05 mm, monoclinic, space group P21/c (no. 14): a =
18.265(5) Å, b =10.935(2) Å, c = 7.857(2) Å, β = 101.60(1)°,
V = 1537.2(6) Å3, Z = 4, ρ(calc) = 1.345 Mg m−3, F(000) =
656, μ = 0.094 mm−1, 4930 reflections (2θmax = 50°), 2685
unique [Rint = 0.128], 212 parameters, 1 restraint, R1 (I > 2σ(I))
= 0.071, wR2 (all data) = 0.185, GOOF = 0.99, largest diff. peak
and hole 0.227/−0.247 e Å−3.
Crystallographic data (excluding structure factors) for the
structures reported in this work have been deposited with the
Cambridge Crystallographic Data Centre as supplementary
publications no.’s CCDC-865479 (9a), CCDC-865480 (9c),
CCDC-865481 (9k), CCDC-865482 (9l), CCDC-965483 (15d),
CCDC-865484 (15f), and CCDC-865485 (16). Copies of
the data can be obtained free of charge on application
to The Director, CCDC, 12 Union Road, Cambridge
DB2 1EZ, UK (Fax: int. code +(1223)336-033; email:
deposit@ccdc.cam.ac.uk).
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